Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT07465120 is registered in ClinicalTrials.gov with Dermavon Holdings Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
- Lead sponsor
- Dermavon Holdings Limited
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- March 20, 2026
- Completion date
- May 31, 2027
- Enrollment
- 160 (estimated)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.
moderate to severe atopic dermatitis